Table 5.

Comparison of total and out-of-pocket costs per year by disease course for disease-modifying therapies (DMTs) during recall period (September 2007 to November 2009).^a,b

	Total cost				OOP cost
	RRMS	SPMS	PPMS	PRMS	RRMS	SPMS	PPMS	PRMS
Mean (SD), US$	20,999 (9502)	20,048 (9427)	19,707 (9367)	19,168 (10,494)	1,073 (4815)	963 (3897)	589 (1434)	824 (2567)
Median, US$	26,327	23,363	22,320	23,436	261	173	187	152
Range, US$	987–58,505	1170–56,483	2808–30,431	914–30,431	0–90,000	0–49,200	0–9684	0–17,465

^aTotal cost is the amount paid by both insurers and patients to the pharmacy. Out-of-pocket cost is the patient component of the total cost. Rebates and coupons are not accounted for due to data limitations. Costs are given in 2009 US dollars.

^bNumber of users by course: RRMS=1165, SPMS=330, PPMS=84, PRMS=60.

Percentage of users in course: RRMS=76.5%, SPMS=62.5%, PPMS=41.8%, PRMS=73.2%.

Percentage of users in sample: RRMS=49.3%, SPMS=14.0%, PPMS=3.6%, PRMS=2.5%.

OOP: out-of-pocket; RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis; PPMS: primary progressive multiple sclerosis; PRMS: progressive-relapsing multiple sclerosis.